Unnamed: 0,title,date,stock,sentiment
1035311.0,Paratek Pharmaceuticals: Q1 Earnings Insights,2020-05-11 07:14:00-04:00,PRTK,neutral
1035312.0,Paratek Pharma Reaffirms FY20 Guidance,2020-05-11 06:51:00-04:00,PRTK,neutral
1035313.0,"Paratek Pharmaceuticals Q1 EPS $(0.66) Beats $(0.80) Estimate, Sales $7.920M Beat $7.460M Estimate",2020-05-11 06:50:00-04:00,PRTK,neutral
1035314.0,Paratek Pharmaceuticals Announces Initiation Of Funding From BARDA For All FDA Required Post-Marketing Studies For NUZYRA,2020-04-02 08:06:00-04:00,PRTK,neutral
1035315.0,Paratek Pharmaceuticals Announces Initiation Of Funding From BARDA For Security Requirements And US Onshoring Of The Manufacturing Supply Chain For NUZYRA,2020-04-01 08:07:00-04:00,PRTK,positive
1035316.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PRTK,neutral
1035317.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,PRTK,negative
1035318.0,Paratek Pharmaceuticals Announces The Submission Of The pre-Emergency Use Authorization Application To The FDA for NUZYRA,2020-03-10 16:04:00-04:00,PRTK,neutral
1035319.0,95 Biggest Movers From Yesterday,2020-02-27 05:18:00-05:00,PRTK,neutral
1035320.0,75 Stocks Moving In Wednesday's Mid-Day Session,2020-02-26 12:18:00-05:00,PRTK,neutral
1035321.0,Paratek Pharma Earlier Said Sees FY20 Sales $75M-$80M vs $68M Estimate,2020-02-25 17:09:00-05:00,PRTK,neutral
1035322.0,"Paratek Pharmaceuticals Q4 EPS $(0.81), Inline, Sales $8.967M Miss $14.84M Estimate",2020-02-25 16:10:00-05:00,PRTK,negative
1035323.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,PRTK,negative
1035324.0,Paratek Pharma Grants the License to Commercialize SEYSARA in China to Almirall,2020-02-24 07:09:00-05:00,PRTK,positive
1035325.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,PRTK,neutral
1035326.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,PRTK,positive
1035327.0,"WBB Securities Initiates Coverage On Paratek Pharmaceuticals with Speculative Buy Rating, Announces $6 Price Target",2020-01-08 09:22:00-05:00,PRTK,positive
1035328.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2020",2020-01-02 10:42:00-05:00,PRTK,positive
1035329.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,PRTK,neutral
1035330.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-23 12:19:00-05:00,PRTK,neutral
1035331.0,21 Stocks Moving in Friday's Pre-Market Session,2019-12-20 07:34:00-05:00,PRTK,neutral
1035332.0,68 Biggest Movers From Yesterday,2019-12-20 04:34:00-05:00,PRTK,neutral
1035333.0,Mid-Afternoon Market Update: Rite Aid Jumps On Upbeat Earnings; Apogee Enterprises Shares Slide,2019-12-19 14:27:00-05:00,PRTK,positive
1035334.0,46 Stocks Moving In Thursday's Mid-Day Session,2019-12-19 12:51:00-05:00,PRTK,neutral
1035335.0,Mid-Day Market Update: Dow Rises Over 100 Points; Minerva Neurosciences Shares Plunge,2019-12-19 12:04:00-05:00,PRTK,positive
1035336.0,Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Tops Estimates,2019-12-19 10:26:00-05:00,PRTK,positive
1035337.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,PRTK,neutral
1035338.0,28 Stocks Moving in Thursday's Pre-Market Session,2019-12-19 08:13:00-05:00,PRTK,neutral
1035339.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,PRTK,negative
1035340.0,Paratek Pharmaceuticals shares are trading higher after the company announced it has been awarded a $285 million BARDA Project BioShield contract to support the development of Paratek's NUZYRA.,2019-12-19 07:42:00-05:00,PRTK,positive
1035341.0,"Paratek Pharma Shares Resume Trade, Up ~80% From Close",2019-12-18 17:41:00-05:00,PRTK,positive
1035342.0,Paratek Reports Wins $285M BARDA Project BioShield Contract For NUZYRA,2019-12-18 17:14:00-05:00,PRTK,positive
1035343.0,Paratek Pharm Shares Halted News Pending,2019-12-18 17:11:00-05:00,PRTK,positive
1035344.0,12 Biotech Stocks Primed For A Short Squeeze,2019-12-06 08:00:00-05:00,PRTK,neutral
1035345.0,81 Biggest Movers From Yesterday,2019-11-14 05:20:00-05:00,PRTK,neutral
1035346.0,54 Stocks Moving In Wednesday's Mid-Day Session,2019-11-13 12:08:00-05:00,PRTK,neutral
1035347.0,Paratek Reaffirms FY19 NUZYRA US Net Product Sales Guidance $10M-$13M,2019-11-12 16:18:00-05:00,PRTK,neutral
1035348.0,"Paratek Pharmaceuticals Q3 EPS $(1) Beats $(1.05) Estimate, Sales $3.1M Miss $3.9M Estimate",2019-11-12 16:17:00-05:00,PRTK,negative
1035349.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,PRTK,neutral
1035350.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,PRTK,positive
1035351.0,61 Biggest Movers From Yesterday,2019-11-06 04:19:00-05:00,PRTK,neutral
1035352.0,Stocks That Hit 52-Week Lows On Friday,2019-11-01 11:13:00-04:00,PRTK,negative
1035353.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,PRTK,neutral
1035354.0,Paratek Offers Top-Line Results Of Phase 2 Studies Of Omadacycline In UTI,2019-10-31 16:23:00-04:00,PRTK,neutral
1035355.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,PRTK,positive
1035356.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,PRTK,neutral
1035357.0,"The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe",2019-10-18 07:07:00-04:00,PRTK,neutral
1035358.0,"Paratek Pharma Reports Withdrew EMA Application For Oral, Intravenous NUZYRA In Skin Infections, Pneumonia",2019-10-17 16:07:00-04:00,PRTK,neutral
1035359.0,42 Biggest Movers From Yesterday,2019-10-04 04:36:00-04:00,PRTK,neutral
1035360.0,Paratek Pharmaceuticals To Present New Data From NUZYRA Development Program At IDWeek 2019,2019-09-25 08:10:00-04:00,PRTK,neutral
1035361.0,46 Biggest Movers From Yesterday,2019-09-24 04:02:00-04:00,PRTK,neutral
1035362.0,65 Biggest Movers From Yesterday,2019-09-18 06:53:00-04:00,PRTK,neutral
1035363.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,PRTK,neutral
1035364.0,65 Biggest Movers From Friday,2019-09-03 05:14:00-04:00,PRTK,neutral
1035365.0,18 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-08-30 08:43:00-04:00,PRTK,neutral
1035366.0,90 Biggest Movers From Yesterday,2019-08-08 05:17:00-04:00,PRTK,neutral
1035367.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,PRTK,neutral
1035368.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-08-07 13:16:00-04:00,PRTK,neutral
1035369.0,Paratek Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-06 17:14:00-04:00,PRTK,positive
1035370.0,"Paratek Pharmaceuticals Q2 EPS $(1.02) Beats $(1.16) Estimate, Sales $2.045M Beat $1.87M Estimate",2019-08-06 16:46:00-04:00,PRTK,neutral
1035371.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,PRTK,positive
1035372.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,PRTK,negative
1035373.0,Paratek Pharma Filing Shows Registration For $50M Common Stock Offering,2019-07-03 06:41:00-04:00,PRTK,neutral
1035374.0,Paratek Pharma Reports Promotion Of Evan Loh To CEO,2019-06-25 16:02:00-04:00,PRTK,neutral
1035375.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,PRTK,negative
1035376.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,PRTK,negative
1035377.0,"Paratek Pharmaceuticals, Inc. - Common Stock Q1 EPS $(0.1) Beats $(1.19) Estimate, Sales $1.598M Up From $10K YoY",2019-05-08 16:52:00-04:00,PRTK,neutral
1035378.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,PRTK,negative
1035379.0,Paratek Pharmaceuticals Highlights Clinical Profile of NUZYRA With New ECCMID 2019 Data Presentations,2019-04-15 16:33:00-04:00,PRTK,neutral
1035380.0,Paratek Pharma To Present New Data From NUZYRA Development Program At ECCMID 2019,2019-04-04 08:32:00-04:00,PRTK,neutral
1035381.0,Paratek Pharma CFO Resigns to Join an Early Stage Biopharma Company,2019-03-18 08:07:00-04:00,PRTK,neutral
1035382.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,PRTK,neutral
1035383.0,"Paratek Pharmaceuticals, Inc. Q4 EPS $(0.71) Misses $(0.69) Estimate, Sales $17.1M Beat $13.29M Estimate",2019-02-27 16:59:00-05:00,PRTK,negative
1035384.0,Paratek Pharma Highlights Publication Of Results from Pivotal Phase 3 Studies of Paratek's NUZYRAâ„¢ (Omadacycline) For Pneumonia and Skin Infections In New England Journal Of Medicine,2019-02-06 17:06:00-05:00,PRTK,neutral
1035385.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,PRTK,neutral
1035386.0,Paratek Pharmaceuticals Launches NUZYRA In The United States,2019-02-05 16:49:00-05:00,PRTK,positive
1035387.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2019",2019-01-02 09:15:00-05:00,PRTK,positive
1035388.0,"Canaccord Genuity Initiates Coverage On Paratek Pharmaceuticals with Buy Rating, Announces $14 Price Target",2019-01-02 08:07:00-05:00,PRTK,neutral
1035389.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,PRTK,neutral
1035390.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,PRTK,positive
1035391.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,PRTK,negative
1035392.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,PRTK,neutral
1035393.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,PRTK,neutral
1035394.0,UPDATE: Paratek Pharma Says Sees NUZYRA Patent Protection Exclusivity Until At Least Oct. 2030,2018-12-03 16:02:00-05:00,PRTK,neutral
1035395.0,"Paratek Pharma Files 2 Patent Term Extensions For '828, '740",2018-12-03 16:01:00-05:00,PRTK,neutral
1035396.0,Paratek Pharma Reports Dosing Of First Patient In Phase 2 Trial Of Omadacycline In Acute Pyelonephritis,2018-11-27 08:04:00-05:00,PRTK,neutral
1035397.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,PRTK,negative
1035398.0,"Paratek Pharmaceuticals, Inc. Q3 EPS $(1.01) Down From $(0.77) YoY, Sales $50K Up From $12K YoY",2018-11-06 16:03:00-05:00,PRTK,neutral
1035399.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,PRTK,positive
1035400.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,PRTK,neutral
1035401.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,PRTK,negative
1035402.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,PRTK,negative
1035403.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,PRTK,positive
1035404.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,PRTK,negative
1035405.0,44 Biggest Movers From Yesterday,2018-10-09 05:27:00-04:00,PRTK,neutral
1035406.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,PRTK,positive
1035407.0,45 Biggest Movers From Yesterday,2018-10-05 06:12:00-04:00,PRTK,neutral
1035408.0,UPDATE: Paratek Says EMA Decision Is Expected During 2H'19,2018-10-04 16:02:00-04:00,PRTK,neutral
1035409.0,"Paratek Pharma Reports Acceptance Of EMA Application For Oral, Intravenous Omadacycline",2018-10-04 16:01:00-04:00,PRTK,positive
1035410.0,"Paratek Pharmaceuticals shares are trading up 15.9%, continuing to gain after the company late Tuesday reported FDA approval for NUZYRA in community-acquired bacterial pneumonia.",2018-10-04 12:54:00-04:00,PRTK,positive
1035411.0,32 Stocks Moving In Thursday's Mid-Day Session,2018-10-04 12:36:00-04:00,PRTK,neutral
1035412.0,"FDA Approves Paratek's Bacterial Pneumonia, Skin Infection Treatment",2018-10-03 12:45:00-04:00,PRTK,positive
1035413.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-10-03 08:10:00-04:00,PRTK,neutral
1035414.0,Paratek Announces FDA Approval of NUZYRA,2018-10-03 04:02:00-04:00,PRTK,positive
1035415.0,"Hearing BTIG Raised Stand-Alone Price Target On Paratek To $38, Price Target In Takeover Deal To $56",2018-10-02 10:21:00-04:00,PRTK,neutral
1035416.0,UPDATE: Paratek Says Earned $12M Milestone Payment,2018-10-02 08:46:00-04:00,PRTK,neutral
1035417.0,Paratek Pharma Reports FDA Approved SEYSARA For Treatment Of Inflammatory Lesions Of Non-Nodular Moderate To Severe Acne Vulgaris In Patients 9+,2018-10-02 08:45:00-04:00,PRTK,positive
1035418.0,"The Week Ahead: Pepsi And Costco Earnings, Upwork IPO",2018-10-01 12:25:00-04:00,PRTK,neutral
1035419.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-30 10:14:00-04:00,PRTK,neutral
1035420.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,PRTK,neutral
1035421.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,PRTK,negative
1035422.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,PRTK,positive
1035423.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,PRTK,negative
1035424.0,"Bank of America Initiates Coverage On Paratek Pharmaceuticals with Neutral Rating, Announces $13 Price Target",2018-08-27 08:43:00-04:00,PRTK,neutral
1035425.0,"Paratek Pharma Shares Open For Trade, Now Up 7.3% at $11.70",2018-08-08 14:51:00-04:00,PRTK,positive
1035426.0,Paratek Pharma Shares To Resume Trade At 2:50 p.m. EDT,2018-08-08 14:26:00-04:00,PRTK,positive
1035427.0,Paratek Press Release Confirms FDA AdCom Panel Recommended Approval Of Its Omadacycline,2018-08-08 14:20:00-04:00,PRTK,positive
1035428.0,FDA Panel Voting On Paratek Antibiotic Voted 14-4 In Favor Of Co. Candidate To Treat Acquired Bacterial Pneumonia,2018-08-08 13:02:00-04:00,PRTK,positive
1035429.0,"Waiting On Official Statement From Paratek Related To An FDA AdCom Panel Vote For Its Skin Infection Antibiotic; Shortly After Official Statement, Nasdaq Should Release A Resume Time",2018-08-08 12:52:00-04:00,PRTK,neutral
1035430.0,"Paratek Shares Halted Ahead Of AdCom Panel; Panel Voted 17-1 In Favor Of Safety, Efficacy For Co.'s Antibiotic",2018-08-08 12:50:00-04:00,PRTK,positive
1035431.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,PRTK,positive
1035432.0,Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee To Review Omadacycline New Drug Applications For Community-Acquired Bacterial Pneumonia And Acute Bacterial Skin And Skin Structure Infections,2018-08-08 07:17:00-04:00,PRTK,neutral
1035433.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,PRTK,neutral
1035434.0,"The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal",2018-08-06 15:30:00-04:00,PRTK,neutral
1035435.0,"Stocks Which Set New 52-Week Lows Friday, August 3rd",2018-08-06 13:20:00-04:00,PRTK,negative
1035436.0,"Stocks Which Set New 52-Week Low Yesterday, August 2nd",2018-08-03 11:22:00-04:00,PRTK,negative
1035437.0,"Paratek Pharmaceuticals, Inc. Q2 EPS $(0.94) Misses $(0.93) Estimate, Sales $40K Inline",2018-08-02 16:31:00-04:00,PRTK,negative
1035438.0,"Stocks Which Set New 52-Week Low Yesterday, August 1st",2018-08-02 11:07:00-04:00,PRTK,negative
1035439.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,PRTK,positive
1035440.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,PRTK,neutral
1035441.0,Paratek Announces FDA Advisory Committee Date Of Aug. 8th 2018 for Omadacycline,2018-06-20 09:07:00-04:00,PRTK,neutral
1035442.0,Paratek Presents New Analysis From Combined Phase 3 Skin Infection Studies Highlighting Efficacy Of Omadacycline In Treating Drug Resistant S. Aureus At ASM Microbe 2018,2018-06-11 08:11:00-04:00,PRTK,neutral
1035443.0,Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching,2018-05-19 16:10:00-04:00,PRTK,positive
1035444.0,"Paratek Pharmaceuticals, Inc. - Common Stock Q1 EPS $(0.91), Inline, Made $10K Sales",2018-05-09 07:32:00-04:00,PRTK,neutral
1035445.0,"Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen",2018-04-25 07:46:00-04:00,PRTK,negative
1035446.0,"Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline at ECCMID, Says On Track to File Marketing Authorization Applications in the EU in 2H 2018",2018-04-23 07:36:00-04:00,PRTK,positive
1035447.0,32 Biggest Movers From Yesterday,2018-04-20 05:42:00-04:00,PRTK,neutral
1035448.0,30 Stocks Moving In Thursday's Mid-Day Session,2018-04-19 12:51:00-04:00,PRTK,neutral
1035449.0,27 Stocks Moving In Thursday's Pre-Market Session,2018-04-19 08:04:00-04:00,PRTK,neutral
1035450.0,Paratek Pharmaceuticals Shares Down 10.2% After Hours On News Of $125M Convertible Debt Offering,2018-04-18 17:41:00-04:00,PRTK,negative
1035451.0,Paratek's NDAs For Oral and Intravenous Omadacycline Accepted For Priority Review by FDA,2018-04-04 16:01:00-04:00,PRTK,positive
1035452.0,Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts,2018-03-13 16:32:00-04:00,PRTK,neutral
1035453.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2018",2018-03-02 09:02:00-05:00,PRTK,positive
1035454.0,Raymond James Downgrades Paratek Pharmaceuticals to Outperform,2018-03-02 08:06:00-05:00,PRTK,neutral
1035455.0,"Paratek Pharma Reports Q4 EPS $(0.78) vs $(1.16) In Same Qtr. Last Year, Net Loss $21.9M, Sales $5.072M vs $29K YoY",2018-03-01 07:14:00-05:00,PRTK,negative
1035456.0,Paratek Completes Submission of NDA to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections,2018-02-05 07:39:00-05:00,PRTK,neutral
1035457.0,38 Biggest Movers From Yesterday,2018-01-19 04:30:00-05:00,PRTK,neutral
1035458.0,Mid-Afternoon Market Update: GNC Surges Following Strong Earnings Guidance; Diffusion Pharmaceuticals Shares Slide,2018-01-18 14:48:00-05:00,PRTK,positive
1035459.0,33 Stocks Moving In Thursday's Mid-Day Session,2018-01-18 12:24:00-05:00,PRTK,neutral
1035460.0,Mid-Morning Market Update: Markets Edge Lower; Morgan Stanley Beats Q4 Estimates,2018-01-18 10:09:00-05:00,PRTK,negative
1035461.0,Paratek Announces Common Stock Public Offering Of $50M,2018-01-17 16:07:00-05:00,PRTK,neutral
1035462.0,Partek Pharma Earns a $5M Milestone Payment From Allergan,2018-01-03 07:10:00-05:00,PRTK,neutral
1035463.0,Paratek Pharma S-3 Filing Shows Registration For $250M Mixed Securities Shelf Offering,2017-12-01 06:11:00-05:00,PRTK,positive
1035464.0,Paratek Pharmaceuticals Reports Q3 EPS $(0.77) vs $(1.04) In Prior Year Period,2017-11-08 07:15:00-05:00,PRTK,neutral
1035465.0,Paratek Pharma Shares Volatile Over Last Few Mins. As Traders Circulate Oct. 27-Dated Bloomberg Gadfly Article 'This Pharma Takeover Target Is Being a Bit Too Obvious'; Stock Now Largely Unaffected vs Prior To Circulation Of Old Report,2017-10-31 15:02:00-04:00,PRTK,positive
1035466.0,"Guggenheim Initiates Coverage On Paratek Pharmaceuticals with Buy Rating, Announces $44.00 Price Target",2017-10-24 09:18:00-04:00,PRTK,neutral
1035467.0,Paratek Phase 3 OPTIC Study Met Primary Endpoint Of Statistical Non-Inferiority In ITT Compared To moxifloxacin For Early Clinical Response,2017-10-06 08:03:00-04:00,PRTK,neutral
1035468.0,Omadacycline Granted Qualified Infectious Disease Product Designation by the FDA for an Additional Indication in Uncomplicated Urinary Tract Infections,2017-09-21 08:03:00-04:00,PRTK,positive
1035469.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Express Shares Rise After Strong Q2 Results,2017-08-23 14:35:00-04:00,PRTK,positive
1035470.0,"Paratek Pharma's 30% Surge, Explained",2017-08-23 12:38:00-04:00,PRTK,neutral
1035471.0,15 Biggest Mid-Day Gainers For Wednesday,2017-08-23 12:18:00-04:00,PRTK,neutral
1035472.0,Mid-Day Market Update: La-Z-Boy Drops After Q1 Miss; Paratek Pharmaceuticals Shares Rise,2017-08-23 12:09:00-04:00,PRTK,positive
1035473.0,Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations,2017-08-23 10:14:00-04:00,PRTK,negative
1035474.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-08-23 08:11:00-04:00,PRTK,neutral
1035475.0,"A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Earnings, Economic Data",2017-08-23 07:06:00-04:00,PRTK,neutral
1035476.0,"Paratek Pharmaceuticals Exploring Strategic Options, Including Potential Sale -Bloomberg",2017-08-23 06:29:00-04:00,PRTK,neutral
1035477.0,Paratek Pharma Shares Up 26% Premarket @$24.00,2017-08-23 06:27:00-04:00,PRTK,positive
1035478.0,"Paratek Pharma Q2 EPS $(0.66) from $(1.69) YoY, Sales $7.51M from $0.00 YoY",2017-08-02 06:18:00-04:00,PRTK,neutral
1035479.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-07-18 08:08:00-04:00,PRTK,neutral
1035480.0,"Paratek Pharma Shares Resume Trade, Now Up 6.6%",2017-07-17 16:39:00-04:00,PRTK,positive
1035481.0,Paratek Pharma Shares To Resume Trade At 4:30 p.m. EDT,2017-07-17 16:29:00-04:00,PRTK,positive
1035482.0,"Paratek Pharma Reports Phase 3 Study Of Oral-Only Dosing Of Omadacycline Met All Primary, Secondary FDA, EMA Endpoints",2017-07-17 16:01:00-04:00,PRTK,neutral
1035483.0,Is The Options Market Predicting A Spike in Paratek Stock?,2017-07-11 14:52:00-04:00,PRTK,neutral
1035484.0,"Paratek's Announces New Microbiology Data Reinforce Activity of Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections",2017-06-03 15:40:00-04:00,PRTK,positive
1035485.0,"Raymond James Initiates Coverage On Paratek Pharmaceuticals with Strong Buy Rating, Announces $36.00 Price Target",2017-05-19 07:23:00-04:00,PRTK,positive
1035486.0,"Wall Street's M&A Chatter From May 4: General Mills, Brookdale Senior Living, Allergan-Paratek",2017-05-05 07:23:00-04:00,PRTK,neutral
1035487.0,Hearing Takeover Chatter in Paratek Pharma,2017-05-04 12:02:00-04:00,PRTK,neutral
1035488.0,Paratek Pharma Pops to High of $22 on Volume,2017-05-04 12:00:00-04:00,PRTK,neutral
1035489.0,Paratek Pharma Q1 EPS $(1.14) vs $1.78 YoY,2017-05-04 09:38:00-04:00,PRTK,neutral
1035490.0,"Paratek Pharma Reports Omadacycline Concentrations Exceed Tigecycline Levels in Lungs, Epithelial Lining Fluid",2017-04-25 07:40:00-04:00,PRTK,neutral
1035491.0,Paratek Pharma Announces Microbiology Data from Phase 3 Trial in Acute Skin Infections Found Once-Daily Treatment with IV-to-Oral Omadacycline Effective in Treating Most-Frequently Isolated Baterial Pathogens Associated with Skin Infections,2017-04-24 07:14:00-04:00,PRTK,positive
1035492.0,Paratek Pharma to Collaborate with Zai Lab for the Development of Omadacycline for use in China,2017-04-24 07:09:00-04:00,PRTK,neutral
1035493.0,18 Biggest Mid-Day Gainers For Tuesday,2017-04-04 12:38:00-04:00,PRTK,neutral
1035494.0,"Paratek Pharmaceuticals Up Nearly 30% After Earlier Wedbush Reiteration With Outperform, Price Target Increase To $34",2017-04-04 10:27:00-04:00,PRTK,positive
1035495.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-04 08:16:00-04:00,PRTK,neutral
1035496.0,"Paratek Pharma Shares Resume, Now Up 21%",2017-04-03 16:34:00-04:00,PRTK,positive
1035497.0,Paratek Pharma Shares to Resume Trade at 4:30 p.m. EDT,2017-04-03 16:08:00-04:00,PRTK,positive
1035498.0,UPDATE: Paratek Says NDA Planned as Early as Q1'18,2017-04-03 16:03:00-04:00,PRTK,neutral
1035499.0,"UPDATE: Paratek Says Omadacycline Was Generally Safe, Well Tolerated",2017-04-03 16:02:00-04:00,PRTK,positive
1035500.0,"Paratek Pharma Reports Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia: Says Met All Primary, Secondary Endpoints",2017-04-03 16:02:00-04:00,PRTK,neutral
1035501.0,Paratek Halted News Pending,2017-04-03 16:00:00-04:00,PRTK,neutral
1035502.0,15 Biggest Mid-Day Gainers For Monday,2017-03-27 12:34:00-04:00,PRTK,neutral
1035503.0,Mid-Morning Market Update: Markets Open Lower; G-III Apparel Misses Q4 Views,2017-03-27 10:28:00-04:00,PRTK,negative
1035504.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-27 08:20:00-04:00,PRTK,neutral
1035505.0,"Allergan and Paratek Announce Phase 3 Trials For Treatment Of Moderate To Severe Acne Meet Primary Endpoints, Program on Track for FDA Submission in the Second Half of 2017",2017-03-27 07:32:00-04:00,PRTK,negative
1035506.0,Watch These 8 Huge Put Purchases In Thursday Trade,2017-03-16 04:01:00-04:00,PRTK,positive
1035507.0,Option Alert: Paratek Pharm Apr 12.5 Puts: 1000 @  ASK  $3.00: 1190 traded vs 4517 OI:  Earnings 5/1 After Close (est)  $16.87 Ref,2017-03-15 12:44:00-04:00,PRTK,positive
1035508.0,Paratek Pharmaceuticals Reports Q4 EPS $(1.16) vs. YoY $(1.20),2017-03-02 07:33:00-05:00,PRTK,neutral
1035509.0,Paratek Pharma Files $225M Mixed Shelf,2016-12-16 06:36:00-05:00,PRTK,neutral
1035510.0,Paratek Advances Expects Phase 3 Top Line Data in Q2 2017,2016-12-13 07:04:00-05:00,PRTK,positive
1035511.0,"Companies Holding Analyst/Investor Days Today Include OncoSec Medical, F5 Networks, Infinera, Qualys, Becton Dickinson & Co, Catabasis Pharmaceuticals, Endologix, Vista Outdoor, And Paratek Pharmaceuticals",2016-11-17 08:30:00-05:00,PRTK,neutral
1035512.0,Paratek Pharmaceuticals Reports Q3 EPS $(1.04) vs. Prior Year Quarter $(1.33),2016-11-02 07:34:00-04:00,PRTK,neutral
1035513.0,Benzinga's Top Initiations,2016-10-27 09:35:00-04:00,PRTK,positive
1035514.0,"Leerink Swann Assumes Paratek Pharmaceuticals, Inc. - Common Stock at Outperform",2016-10-27 07:08:00-04:00,PRTK,neutral
1035515.0,Paratek Starts Final Stage Study Of Oral-only Omadacycline In ABSSSI,2016-08-15 09:24:00-04:00,PRTK,neutral
1035516.0,Paratek Pharmaceuticals Reports Q2 EPS $(1.69) vs. Prior Year Quarter $(0.96),2016-08-04 07:07:00-04:00,PRTK,neutral
1035517.0,Paratek Closes Common Stock Offering Announced Last Week For Net Proceeds Of $59.7M,2016-06-27 12:05:00-04:00,PRTK,neutral
1035518.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-06-22 08:18:00-04:00,PRTK,neutral
1035519.0,Paratek Pharma Prices 4.25M Share Offering at $13/Share,2016-06-22 08:03:00-04:00,PRTK,positive
1035520.0,Mid-Afternoon Market Update: Werner Enterprises Slides Following Weak Guidance; Imperva Shares Spike Higher,2016-06-21 14:31:00-04:00,PRTK,negative
1035521.0,8 Biggest Mid-Day Losers For Tuesday,2016-06-21 12:56:00-04:00,PRTK,negative
1035522.0,Paratek Reports Proposed Public Stock Offering,2016-06-20 16:01:00-04:00,PRTK,neutral
1035523.0,"UPDATE: Paratek Says Will Report Top-Line Data in Q4'16, Had Previously Expected Q1'17",2016-06-20 08:03:00-04:00,PRTK,neutral
1035524.0,Paratek Reports Acceleration of Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Study,2016-06-20 08:02:00-04:00,PRTK,neutral
1035525.0,"Cantor Raises Price Target For Paratek Pharma, Sees 82% Upside",2016-06-17 17:08:00-04:00,PRTK,neutral
1035526.0,11 Biggest Mid-Day Gainers For Friday,2016-06-17 12:34:00-04:00,PRTK,neutral
1035527.0,Benzinga's Volume Movers,2016-06-17 10:51:00-04:00,PRTK,neutral
1035528.0,15 Stocks Moving In Friday's Pre-Market Session,2016-06-17 08:18:00-04:00,PRTK,neutral
1035529.0,Ladenburg Thalmann Maintains Buy on Paratek Pharmaceuticals,2016-06-17 07:23:00-04:00,PRTK,neutral
1035530.0,Paratek Shares Resume at $22.20 Up 40%,2016-06-16 16:38:00-04:00,PRTK,positive
1035531.0,Paratek Pharma shares to resume trading at 4:35pmEDT,2016-06-16 16:22:00-04:00,PRTK,positive
1035532.0,Paratek Reports that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated,2016-06-16 16:06:00-04:00,PRTK,positive
1035533.0,"Paratek Halted, News Pending",2016-06-16 16:03:00-04:00,PRTK,neutral
1035534.0,Paratek Pharma Announces Received FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study,2016-05-10 16:35:00-04:00,PRTK,neutral
1035535.0,"Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets, Potential To Include Oral-Only Study In Proj. NDA In 1H 2018",2016-05-10 16:01:00-04:00,PRTK,positive
1035536.0,Paratek Initiates Phase 1b Study of Omadacycline in Urinary Tract Infection,2016-05-02 16:47:00-04:00,PRTK,neutral
1035537.0,Paratek Pharma Offers Pre-Clinical Data on Effects of Omadacycline on Clostridium Difficile,2016-04-11 07:31:00-04:00,PRTK,neutral
1035538.0,"Cantor Fitzgerald Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $27.00 PT",2016-03-29 16:47:00-04:00,PRTK,neutral
1035539.0,Benzinga's Top Initiations,2016-02-29 09:51:00-05:00,PRTK,positive
1035540.0,"H.C. Wainwright Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $32.00 PT",2016-02-29 07:13:00-05:00,PRTK,neutral
1035541.0,Paratek Pharma. Reports Q4 EPS $(1.20) vs. Prior Year Quarter $(1.16),2016-02-23 07:13:00-05:00,PRTK,neutral
1035542.0,"UPDATE: Paratek Reports Unaudited Cash, Cash Equivalents of ~$131.3M as of Dec. 31, 2015",2016-01-06 07:08:00-05:00,PRTK,neutral
1035543.0,Paratek Release Confirms Earlier-Reported Acceleration of timing for Projected Reporting of Top-Line Data for Omadacycline Trial,2016-01-06 07:07:00-05:00,PRTK,neutral
1035544.0,Paratek Pharma Reports Q3 EPS $(1.33),2015-11-12 07:03:00-05:00,PRTK,neutral
1035545.0,Paratek Starts Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP),2015-11-09 07:32:00-05:00,PRTK,neutral
1035546.0,Paratek Receives FDA Fast Track Designation for Omadacycline,2015-11-04 16:11:00-05:00,PRTK,neutral
1035547.0,Paratek Pharmaceuticals Files for Mixed Shelf of Up to $100 M,2015-10-16 06:06:00-04:00,PRTK,neutral
1035548.0,Leerink: Time To Buy Nabriva Therapeutics' 'Unique Differentiation',2015-10-13 08:49:00-04:00,PRTK,neutral
1035549.0,"Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-acquired Pneumonia and Urinary Tract Infections",2015-09-20 15:56:00-04:00,PRTK,neutral
1035550.0,"Paratek Announces Omadacycline Showed Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-Acquired Pneumonia, UTI",2015-09-17 07:33:00-04:00,PRTK,neutral
1035551.0,"Paratek Pharmaceuticals Reports Q2 EPS $(0.96), Estimates Not Available",2015-08-05 07:09:00-04:00,PRTK,neutral
1035552.0,Paratek Reports Termination Of Tax Benefit Preservation Plan,2015-07-24 16:05:00-04:00,PRTK,positive
1035553.0,"Gabelli Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $34.00 PT",2015-07-22 09:02:00-04:00,PRTK,neutral
1035554.0,UPDATE: Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections,2015-06-23 09:08:00-04:00,PRTK,neutral
1035555.0,Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections,2015-06-23 09:08:00-04:00,PRTK,neutral
1035556.0,"BTIG Research Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $45.00 PT",2015-05-27 09:17:00-04:00,PRTK,neutral
1035557.0,Leerink Swann Initiates Paratek Pharmaceuticals With Outperform,2015-05-15 09:58:00-04:00,PRTK,neutral
1035558.0,Benzinga's Top Initiations,2015-05-15 09:47:00-04:00,PRTK,positive
1035559.0,"Leerink Swann Initiates Coverage on Paratek Pharmaceuticals at Outperform, Announces $43.00 PT",2015-05-15 07:33:00-04:00,PRTK,neutral
1035560.0,Cantor Slaps 'Buy' Rating On Paratek Pharmaceuticals,2015-05-12 09:16:00-04:00,PRTK,neutral
1035561.0,Benzinga's Top Initiations,2015-05-12 09:15:00-04:00,PRTK,positive
1035562.0,Cantor Fitzgerald Initiates Paratek Pharmaceuticals At Buy,2015-05-12 08:53:00-04:00,PRTK,neutral
1035563.0,"Cantor Fitzgerald Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $35.00 PT",2015-05-12 06:11:00-04:00,PRTK,neutral
1035564.0,Benzinga's Top Initiations,2015-05-11 09:26:00-04:00,PRTK,positive
1035565.0,Guggenheim Securities Initiates Paratek Pharmaceuticals At Buy,2015-05-11 08:45:00-04:00,PRTK,positive
1035566.0,"Guggenheim Securities Initiates Coverage on Paratek Pharmaceuticals at Buy, Announces $37.00 PT",2015-05-11 06:44:00-04:00,PRTK,positive
1035567.0,Paratek Prices 2.86M Share Offering @$24.50/Share,2015-04-30 04:40:00-04:00,PRTK,positive
1035568.0,Paratek Announces Offering Of $60M Stock,2015-04-27 16:02:00-04:00,PRTK,neutral
1035569.0,"Klarman-Founded Baupost Group Increases Stake In eBay, Trims Micron and Citigroup In Q4",2015-02-14 19:49:00-05:00,PRTK,neutral
1035570.0,S-3: Paratek Pharma Files $200M Shelf Offering,2015-01-12 16:59:00-05:00,PRTK,neutral
1035571.0,Paratek Announces Received $4M Payment from Actavis Related to Initiation of Phase 3 Trial of Sarecycline,2015-01-06 08:04:00-05:00,PRTK,neutral
